Abstract

Hyperglycosylated proteins are more stable, show increased serum half-life and less sensitivity to proteolysis compared to non-sialylated forms. This applies particularly to recombinant human erythropoietin (rhEPO). Recent progress in N-glycoengineering of non-mammalian expression hosts resulted in in vivo protein sialylation at great homogeneity. However the synthesis of multi-sialylated N-glycans is so far restricted to mammalian cells. Here we used a plant based expression system to accomplish multi-antennary protein sialylation. A human erythropoietin fusion protein (EPOFc) was transiently expressed in Nicotiana benthamiana ΔXTFT, a glycosylation mutant that lacks plant specific N-glycan residues. cDNA of the hormone was co-delivered into plants with the necessary genes for (i) branching (ii) β1,4-galactosylation as well as for the (iii) synthesis, transport and transfer of sialic acid. This resulted in the production of recombinant EPOFc carrying bi- tri- and tetra-sialylated complex N-glycans. The formation of this highly complex oligosaccharide structure required the coordinated expression of 11 human proteins acting in different subcellular compartments at different stages of the glycosylation pathway. In vitro receptor binding assays demonstrate the generation of biologically active molecules. We demonstrate the in planta synthesis of one of the most complex mammalian glycoforms pointing to an outstanding high degree of tolerance to changes in the glycosylation pathway in plants.

Highlights

  • Recombinant human erythropoietin was the first hematopoietic growth factor approved to treat anemia associated with kidney failure, cancer and other pathological conditions [1]

  • Protein A purified rhEPOFc fractionated by SDS PAGE and stained with Coomassie-brilliant blue R-250. lane 1: rhEPOFc expressed in N. benthamiana mutants lacking plant specific b1,2-xylose and a1,3-fucose; lane 2: rhEPOFc co-expressed with mammalian genes for protein sialylation (GNE, NANS, CMAS, CST, STGalT and ST); lane 3: rhEPOFc co-expressed with mammalian genes necessary for sialylation and synthesis of tri-antennary N-glycans GnTIV or GnTV,; lane 4: rhEPOFc co-expressed with mammalian genes for sialylation and synthesis of tetraantennary N-glycans, GnTIV and GnTV

  • Several proteins in total soluble protein (TSP) and the 55 kDa protein band corresponding to intact rhEPOFc reacted to JIM 84 revealing the presence of N-glycans with Lewis-a epitopes. (M) protein marker

Read more

Summary

Introduction

Recombinant human erythropoietin (rhEPO) was the first hematopoietic growth factor approved to treat anemia associated with kidney failure, cancer and other pathological conditions [1]. Glycosylation has a profound effect in maintaining the overall stability and in vivo hematopoietic activity of hEPO [4,5,6]. Several studies report that terminal sialic acid increases the circulatory half- life of rhEPO, a positive correlation between the in vivo biological activity and the ratio of tetra- to bi-antennary sialylated oligosaccharides was shown [7,8]. Hyper-sialylated rhEPOs with prolonged half-life and subsequent enhanced drug efficacy were produced [6]. Another strategy to improve drug efficacy of rhEPO is its fusion to stabilizing peptides/proteins. EPOFc fusions have been successfully explored in this direction [15]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call